HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
-
Citations
127 Claims
-
1-88. -88. (canceled)
-
89. A pharmaceutical composition comprising a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof;
- a further therapeutic agent; and
a pharmaceutically acceptable carrier. - View Dependent Claims (90, 91, 92, 93, 94, 95, 96, 125, 126, 127)
- a further therapeutic agent; and
- 97. A method of treating a disease selected from cachexia, a myeloproliferative disorder and cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound that is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and a further therapeutic agent.
-
110. (canceled)
Specification